Simple Method Could Monitor Treatment Efficacy in Lung Cancer

Nivolumab (Opdivo®, Bristol-Myers Squibb), a checkpoint inhibitor, can help the immune system combat cancer cells. However, each patient responds to this treatment differently and needs to be monitored accordingly to gauge how it is interacting with the body. Researchers at Osaka University have devised a simple method for testing the impact of nivolumab. By analyzing small samples of blood and lung fluid in non-small cell lung cancer (NSCLC) patients, the researchers were able to measure the am...
Continue reading

Liquid Biopsy Introduced to Immunotherapy Response Trial

Personal Genome Diagnostics, Inc. (PGDx) has announced that its non-invasive pan-cancer plasma assay will be used in a new clinical trial to identify POLE and POLD1 mutations in solid tumors and investigate whether those tumor types respond to immunotherapy. POLE and POLD1 are associated with heightened mutation rates in tumor DNA, as well as better response to nivolumab and ipilimumab. The study will evaluate the efficacy and safety of nivolumab alone and in combination with ipilimumab in 100 p...
Continue reading

Nanoparticles Enhance Chemotherapy Response

By combining tumor-modulating nanoparticles with chemotherapy regimens such as doxorubicin, scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have found a method to enhance chemotherapeutic efficacy and boost antitumor immunity. The researchers introduced hybrid polymer-lipid encapsulated manganese dioxide nanoparticles (PLMD NP) in breast cancer mouse models. These nanoparticles function by accumulating in the tumor and remodeling the tumor environment by generating oxyge...
Continue reading

FDA Approves Cemiplimab for Cutaneous Squamous Cell Carcinoma

The FDA has approved cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals, Inc.) for intravenous treatment of metastatic cutaneous squamous cell carcinoma (CSCC) and for treatment of locally advanced CSCC in patients ineligible for curative surgery or radiation. Cemiplimab is the first drug approved specifically for the treatment of advanced CSCC. It targets the PD-1 (programmed cell death protein-1) cellular pathway found in the body's immune cells, helping the body's immune system to combat ca...
Continue reading

Study Reveals How Merkel Cell Carcinoma Eludes Immunotherapy

Researchers at the Fred Hutchinson Cancer Research Center have discovered a source of tumor recurrence in patients with Merkel cell carcinoma who initially show response to immunotherapy treatments. Around 20% of patients with Merkel cell carcinoma experience relapse and subsequent resistance to T-cell therapy. The cause of this relapse remained unknown until the Immunotherapy Integrated Research Center at Fred Hutch more closely examined the molecular changes. Two patients with Merkel cell carc...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.